anti- UBE2C antibody
Background:
Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'-and 'Lys-48'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome(APC/C), a cell cycle-regulated ubiquitin ligase that controls progression through mitosis. Acts by initiating 'Lys-11'-linked polyubiquitin chains on APC/C substrates, leading to the degradation of APC/C substrates by the proteasome and promoting mitotic exit.
Clonality:
monoclonal
Classification:
Primary antibody
Alternative names:
DJ447F3.2, UBCH10, UBE2C, Ubiquitin carrier protein C, Ubiquitin protein ligase C
Specificity:
Human
Host:
Mouse
Isotype:
IgG1
Immunogen:
ubiquitin-conjugating enzyme E2C
Purification:
Protein A+G purification
Purity:
≥95% as determined by SDS-PAGE
Calculated molecular weight:
20 kDa
Form:
liquid
Applications:
ELISA, IF, IHC, WB
Recommended dilution:
WB: 1:500-1:5000; IHC: 1:20-1:200;IF: 1:10-1:100
Storage:
PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.